OpGen Inc(NASDAQ:OPGN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $1.18M. Analysts estimated a revenue of $1.10M. Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.28.
In a different note, Rodman & Renshaw said it Initiates Coverage on OpGen Inc, according to a research note issued on Jun 29, 2016. The shares have been rated ‘Buy’ by the firm.
OpGen Inc (OPGN) shares turned negative on Wednesdays trading session with the shares closing down -0.03 points or -1.60% at a volume of 1,77,702. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.94. The peak price level was also seen at $1.94 while the days lowest was $1.788. Finally the shares closed at $1.84. The 52-week high of the shares is $4.65 while the 52-week low is $1.02. According to the latest information available, the market cap of the company is $40 M.
Several Insider Transactions has been reported to the SEC. On May 23, 2016, Kevin Krenitsky (President) purchased 43,716 shares at $0.00 per share price.Also, On May 23, 2016, Capital, Llc Jven (10% owner) purchased 874,317 shares at $0.00 per share price.On May 23, 2016, Evan/ Fa Jones (CEO) purchased 874,317 shares at $0.00 per share price, according to the Form-4 filing with the securities and exchange commission.
OpGen Inc. is a United States-based Company that provides optical mapping solutions for life sciences. The Company offers optical mapping services for analysis of microbial yeast and fungal genomic architecture. It offers its optical mapping technology for life science clinical and food microbiology life science epidemiology pharmacology microbial forensics manufacturing quality control and applied research applications. Its map analysis software module includes with the Argus Whole Genome Mapping System which provides analysis for microbial samples and genomes up to 100Mb.